BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23932394)

  • 1. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hasselbalch HC
    Leuk Res; 2014 Feb; 38(2):263-6. PubMed ID: 23932394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
    Hasselbalch HC
    Leuk Res; 2013 Feb; 37(2):214-20. PubMed ID: 23174192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Differential diagnosis of myeloproliferative neoplasms. Quantitative NF-E2 immunohistochemistry for differentiating between essential thrombocythemia and primary myelofibrosis].
    Aumann K; Frey AV; May AM; Hauschke D; Kreutz C; Marx JP; Timmer J; Werner M; Pahl HL
    Pathologe; 2013 Nov; 34 Suppl 2():201-9. PubMed ID: 24196613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
    Hasselbalch HC
    Blood; 2012 Apr; 119(14):3219-25. PubMed ID: 22318201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
    Hasselbalch HC
    Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development.
    Andersen M; Sajid Z; Pedersen RK; Gudmand-Hoeyer J; Ellervik C; Skov V; Kjær L; Pallisgaard N; Kruse TA; Thomassen M; Troelsen J; Hasselbalch HC; Ottesen JT
    PLoS One; 2017; 12(8):e0183620. PubMed ID: 28859112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.
    Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
    Leuk Res; 2012 Nov; 36(11):1387-92. PubMed ID: 22877729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Yigit N; Covey S; Barouk-Fox S; Turker T; Geyer JT; Orazi A
    Hum Pathol; 2015 Aug; 46(8):1217-25. PubMed ID: 26093937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial chronic myeloproliferative disorders: the state of the art.
    Rumi E
    Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.
    Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
    Eur J Haematol; 2011 Jul; 87(1):54-60. PubMed ID: 21447007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
    Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
    Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
    [No Abstract]   [Full Text] [Related]  

  • 19. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.